Dr. Martens

DOCS · Main Market · Consumer Products and Services · mcap £658m · 65.6p 1 open situation →

Beta Briefing, track record and signals & risks are not ready for Dr. Martens yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

20252026 Levers for Growth strategy 1 director buying 2 directors buying 1 director buying 3 directors buying

Open · 1

Turnaround plan with targets

Levers for Growth strategy

Scale phase, on track in early FY27

Levers for Growth strategy: the pivot phase finished and the scale phase began in FY27. The AGM update says the company is on track with its four FY27 objectives. These are full price mix in UK and DACH, a new sandals range, new retail concepts in key cities, and operating model and technology benefits. No figures given.

FY27 objectives: Full price mix in UK and DACH; new sandals range; new retail concepts in key cities; operating model and technology benefits
Progress: On track with strategic objectives for FY27, per AGM update on 15 July 2026
Regional trading: USA growing, wholesale encouraging; Japan and South Korea performing well; Europe as expected

15 Jul 2026 Scale phase, on track in early FY27
19 May 2026 Pivot phase done; scale phase starting FY27
8 Apr 2026 Executing; market GM structure and Executive Team installed
27 Jan 2026 Executing; wholesale and Americas progressing, EMEA DTC weak

Open the full view – chart and every step →

Closed · 4

Insider conviction1 director buying £156k in 2 buys · 8 Dec 2025 – 12 Mar 2026 −8% Insider conviction2 directors buying £79k in 2 buys · 28 Jul 2025 – 26 Oct 2025 −10% Insider conviction1 director buying £18k in 1 buy · 26 Mar 2025 – 24 Jun 2025 +73% Insider conviction3 directors buying £65k in 3 buys · 27 Aug 2024 – 25 Dec 2024 −11%

Company filings. Not investment advice.